DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Information source: Fundació Sant Joan de Déu
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Reboxetine (Drug); citalopram (SSRI) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Fundació Sant Joan de Déu

Overall contact:
Judith Usall U R, DRA., Phone: 936002650, Ext: 2356, Email: jusall@pssjd.org

Summary

Main objective: To assess the efficacy of two antidepressants of different pharmacological families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine (Norepinephrine Reuptake inhibitor, NRI) as adjunct treatments to risperidone and olanzapine for the treatment of negative symptoms of schizophrenia. Secondary objectives: To assess the efficacy of citalopram and reboxetine as adjunct treatments to risperidone and olanzapine for the treatment of cognitive symptoms of schizophrenia. To compare the efficacy of reboxetine and citalopram as adjunct treatments for the treatment of negative and cognitive symptoms of schizophrenia. Method: Multicentric, randomized double-blind clinical trial compared to placebo with a six months follow-up. A total of 249 patients with a diagnosis of schizophrenia (DSM-IV criteria) and significant negative symptoms, will be recruited in the 9 participating centres. Variables: sociodemographic and clinical variables (PANSS, SANS, CGI global, GAF,LSP, Hamilton scale, BACS)

Clinical Details

Official title: Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: The primary efficacy end-point will be the change in the score of the PANSS negative subscale from baseline to follow-up assessment.

Secondary outcome: Secondary efficacy endpoints will be the change in the scores of the total PANSS and all the other clinical, social and neuropsychological scales from baseline to follow-up evaluation.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of schizophrenia (DSM-IV criteria)

- Stable doses of antipsychotic medication (olanzapine, risperidone)for at least 60

days prior to study initiation

- Presence of significant negative symptoms (defined as one or more negative symptom

score grater than 4 in the PANSS scale) (Kay 1987)

- Patients have to give written informed consent to participate in the study

Exclusion Criteria:

- Patients with a substance abuse/dependence diagnosis in the previous six months.

- Mental Retardation.

- Patients taking antidepressant in the last 4 months before the trial.

- Patients taking other antipsychotic medication, except: sinquan 100, Entumine 40,

Largactil 100 and Seroquel 200.

- Patients who score more than 20 in Hamilton Rating Scale for Depression.

- Pregnancy or lactation.

- Serious impaired kidney function.

- History of hemorrhagic disorders.

- Reboxetine or citalopram allergy.

Locations and Contacts

Judith Usall U R, DRA., Phone: 936002650, Ext: 2356, Email: jusall@pssjd.org

Parc Sanitari Sant Joan de Déu, Sant Boi Llobregat, Barcelona, Spain; Recruiting
Judith Usall, Phone: 93 6002650, Ext: 2356, Email: jusall@pssjd.org
Additional Information

Starting date: November 2008
Last updated: February 18, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017